about
Specific and nontoxic silencing in mammalian cells with expressed long dsRNAs.Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expressionCiclopirox inhibits cancer cell proliferation by suppression of Cdc25A.Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction.Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression.Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells.Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cellsDihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cellsProtothecosis: report of a case with 20-year follow-up, and review of previously published cases.Myeloid Wnt ligands are required for normal development of dermal lymphatic vasculature.Adenoviral delivery of Tousled kinase for the protection of salivary glands against ionizing radiation damage.Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming.eIF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival.Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.YAP/TAZ-CDC42 signaling regulates vascular tip cell migration.A novel technique of axillary vein puncture involving peripherally inserted central venous catheters for a small basilic vein.Medical phycology 2017.Developmental vascular regression is regulated by a Wnt/β-catenin, MYC, P21 (CDKN1A) pathway that controls cell proliferation and cell death.An opsin 5-dopamine pathway mediates light-dependent vascular development in the eye
P50
Q33254360-A69C1E02-A369-4C82-A31B-43B51557F2A7Q33486534-56D8F8C8-0AF9-4251-A014-82C24A90EE0FQ33849693-196C6C68-C80E-4D1D-8063-1DF69149AF66Q34675574-6E3868DB-08A5-40B9-9A35-D23905CF86D4Q35882208-4420983C-ABE8-494B-9D6C-790BD6F52096Q35883582-1B225CCA-EBA7-4E55-8084-94821B30004EQ36136572-0AE67216-AB4E-45BA-B67D-3974CA09790BQ37412018-B533C650-FFB3-4D04-824C-8C815F037B24Q38008759-7BF5F21B-D3D7-4FD2-8F30-718494D4EDCAQ38605713-C54FF749-DED4-4649-BAE5-70E93FF7C283Q39277352-C7963C50-E028-4DBD-B8C4-648AFFDE3170Q39753154-9994EEB1-3E8C-4D91-B36E-F7A431B49859Q39969617-CBCF6D28-B538-46BE-A2D4-A89724810DC0Q40262542-AED6B7A7-6DAC-4C19-A496-DE7B00FF935AQ49647076-4EBD49BF-348D-4ACC-8A86-8310E7B6C640Q52625207-87D0FCEE-6468-404F-9104-5D4DD91B2E49Q54210232-2573996F-8E41-4637-B127-4EF65CFDE950Q54978768-CAC18B71-BA0D-4713-BC56-2A807B9C1692Q92767381-B349C49B-7989-4CDF-AC54-2FD2EB0FAF4C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yoshinobu Odaka
@ast
Yoshinobu Odaka
@en
Yoshinobu Odaka
@es
Yoshinobu Odaka
@nl
type
label
Yoshinobu Odaka
@ast
Yoshinobu Odaka
@en
Yoshinobu Odaka
@es
Yoshinobu Odaka
@nl
prefLabel
Yoshinobu Odaka
@ast
Yoshinobu Odaka
@en
Yoshinobu Odaka
@es
Yoshinobu Odaka
@nl
P106
P31
P496
0000-0003-3966-5475